UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010198
Receipt number R000011945
Scientific Title Compare efficacy and safety of alpha1-blockers in patients with benign prostatic hyperplasia
Date of disclosure of the study information 2013/03/11
Last modified on 2015/09/09 10:10:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Compare efficacy and safety of alpha1-blockers in patients with benign prostatic hyperplasia

Acronym

Compare the treatment of the alpha1-blockers

Scientific Title

Compare efficacy and safety of alpha1-blockers in patients with benign prostatic hyperplasia

Scientific Title:Acronym

Compare the treatment of the alpha1-blockers

Region

Japan


Condition

Condition

Benign Prostatic Hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the treatment of Tamsulosin and Naftopidil in patients with benign prostatic hyperplasia

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

International Prostate Symptom Score
BPH Impact Index

Key secondary outcomes

Blood Pressure


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Tamusulosin
8 weeks
0.2 mg
once a day

Interventions/Control_2

Naftopidil
8 weeks
75 mg
once a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1)The patients aged more than 50 years who written informed consent was obtained .
2)The patients who had a diagnosis of bengin prostatic hyperplasia with non-treatment.
3)I-PSS total score higher than 8 and QOL score higher than 2

Key exclusion criteria

1)Patients who have taken a medicine that influence on the urination function.
2)Patients with suspected prostate cancer.
3)Patients with suspected Neurogenic Bladder.
4)Patients with urethral stricture.
5)Patients who gave radiotherapy in the pelvis.
6)Patients with urinary tract infection, calculus urinary, cystitis interstitial.
7)Patients with serious impaired liver function, serious renal dysfunction, serious heart disorder.
8)Patients with orthostatic hypotension.
9)Patients with myasthenia gravis.
10)Maximum urinary flow rate=>15mL/s
11)The inappropriate patients who is judged by urologist.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masami Matsushita

Organization

Matsushita Urologocal Clinic

Division name

Department of Urology

Zip code


Address

459 Minamitada, Kaibara-cho, Tanba-shi, Hyogo-ken, Japan

TEL

0795-73-0266

Email

kzkk77731@leto.eonet.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masami Matsushita

Organization

Matsushita Urologocal Clinic

Division name

Department of Urology

Zip code


Address

459 Minamitada, Kaibara-cho, Tanba-shi, Hyogo-ken, Japan

TEL

0795-73-0266

Homepage URL


Email

kzkk77731@leto.eonet.ne.jp


Sponsor or person

Institute

Matsushita Urologocal Clinic

Institute

Department

Personal name



Funding Source

Organization

Astellas Pharma Inc

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

松下泌尿器科医院(兵庫県)


Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 01 Month 17 Day

Date of IRB


Anticipated trial start date

2012 Year 02 Month 12 Day

Last follow-up date

2014 Year 09 Month 30 Day

Date of closure to data entry

2014 Year 11 Month 25 Day

Date trial data considered complete

2014 Year 11 Month 25 Day

Date analysis concluded

2014 Year 12 Month 11 Day


Other

Other related information



Management information

Registered date

2013 Year 03 Month 09 Day

Last modified on

2015 Year 09 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011945


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name